Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Sq 26900
2. Sq 26991
3. Sq-26900
4. Sq-26991
5. Zofenil
6. Zofenopril
7. Zofenopril, Calcium Salt, (1(r*),2alpha,4alpha)-isomer
8. Zofil
1. 81938-43-4
2. Zofenopril Calcium Salt
3. Zoprace
4. Zofenopril Calcium [usan]
5. Sq 26991
6. Chebi:82600
7. 81938-43-4 (calcium)
8. 88zq329pu2
9. Zofenoprilcalcium
10. Sq-26991
11. Zofenopril Calcium (usan)
12. Calcium (2s,4s)-1-((s)-3-(benzoylthio)-2-methylpropanoyl)-4-(phenylthio)pyrrolidine-2-carboxylate
13. Unii-88zq329pu2
14. Bifril-d5
15. Zoprace (tn)
16. Ncgc00182038-01
17. Dsstox_cid_28551
18. Dsstox_rid_82823
19. Dsstox_gsid_48625
20. Schembl641349
21. Chembl2105776
22. Dtxsid1048625
23. Zofenopril Calcium [mart.]
24. Zofenopril Calcium [who-dd]
25. Tox21_112966
26. Mfcd08704648
27. Zofenopril Calcium Salt [mi]
28. Akos015840019
29. Akos015967030
30. Ac-4336
31. (4s)-n-((s)-3-mercapto-2-methylpropionyl)-4-(phenylthio)-l-proline Benzoate (ester), Calcium Salt
32. As-81847
33. So 26991
34. Cas-81938-43-4
35. Zofenopril Calcium, >98% (hplc), Powder
36. Z0041
37. D03767
38. A840224
39. Q-101025
40. Q27156118
41. (4s)-n-((s)-3-mercapto-2-methylpropionyl)-4-(phenylthio)-r-proline Benzoate (ester), Calcium Salt
42. [1(s),4(s)]-1-(3-mercapto-2-methyl-1-oxopropyl)-4-phenyl-thio-l-proline-s-benzoyl Ester Calcium Salt
43. Bis[1-[(s)-3-(benzoylthio)-2-methyl-1-oxopropyl]-4alpha-(phenylthio)-l-proline] Calcium Salt
44. Calcium (2r,4r)-1-[(2s)-3-benzoylsulfanyl-2-methyl-propanoyl]-4-phenylsulfanyl-pyrrolidine-2-carboxylate
45. Calcium Bis[(2s,4s)-1-[(2s)-3-(benzoylsulfanyl)-2-methylpropanoyl]-4-(phenylsulfanyl)pyrrolidine-2-carboxylate]
46. Calcium;(2s,4s)-1-[(2s)-3-benzoylsulfanyl-2-methylpropanoyl]-4-phenylsulfanylpyrrolidine-2-carboxylate
47. L-proline, 1-(3-(benzoylthio)-2-methyl-1-oxopropyl)-4-(phenylthio)-, Calcium Salt, (1(r*),2alpha,4alpha)-
48. R-proline, 1-(3-(benzoylthio)-2-methyl-1-oxopropyl)-4-(phenylthio)-, Calcium Salt, (1(r*),2.alpha.,4.alpha.)-
Molecular Weight | 897.2 g/mol |
---|---|
Molecular Formula | C44H44CaN2O8S4 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 14 |
Exact Mass | 896.1606419 g/mol |
Monoisotopic Mass | 896.1606419 g/mol |
Topological Polar Surface Area | 256 Ų |
Heavy Atom Count | 59 |
Formal Charge | 0 |
Complexity | 582 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 6 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
Angiotensin-Converting Enzyme Inhibitors
A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Market Place
ABOUT THIS PAGE
19
PharmaCompass offers a list of Zofenopril Calcium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Zofenopril Calcium manufacturer or Zofenopril Calcium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Zofenopril Calcium manufacturer or Zofenopril Calcium supplier.
PharmaCompass also assists you with knowing the Zofenopril Calcium API Price utilized in the formulation of products. Zofenopril Calcium API Price is not always fixed or binding as the Zofenopril Calcium Price is obtained through a variety of data sources. The Zofenopril Calcium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Zoprace (TN) manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Zoprace (TN), including repackagers and relabelers. The FDA regulates Zoprace (TN) manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Zoprace (TN) API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Zoprace (TN) manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Zoprace (TN) supplier is an individual or a company that provides Zoprace (TN) active pharmaceutical ingredient (API) or Zoprace (TN) finished formulations upon request. The Zoprace (TN) suppliers may include Zoprace (TN) API manufacturers, exporters, distributors and traders.
click here to find a list of Zoprace (TN) suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Zoprace (TN) DMF (Drug Master File) is a document detailing the whole manufacturing process of Zoprace (TN) active pharmaceutical ingredient (API) in detail. Different forms of Zoprace (TN) DMFs exist exist since differing nations have different regulations, such as Zoprace (TN) USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Zoprace (TN) DMF submitted to regulatory agencies in the US is known as a USDMF. Zoprace (TN) USDMF includes data on Zoprace (TN)'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Zoprace (TN) USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Zoprace (TN) suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Zoprace (TN) Drug Master File in Korea (Zoprace (TN) KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Zoprace (TN). The MFDS reviews the Zoprace (TN) KDMF as part of the drug registration process and uses the information provided in the Zoprace (TN) KDMF to evaluate the safety and efficacy of the drug.
After submitting a Zoprace (TN) KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Zoprace (TN) API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Zoprace (TN) suppliers with KDMF on PharmaCompass.
A Zoprace (TN) written confirmation (Zoprace (TN) WC) is an official document issued by a regulatory agency to a Zoprace (TN) manufacturer, verifying that the manufacturing facility of a Zoprace (TN) active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Zoprace (TN) APIs or Zoprace (TN) finished pharmaceutical products to another nation, regulatory agencies frequently require a Zoprace (TN) WC (written confirmation) as part of the regulatory process.
click here to find a list of Zoprace (TN) suppliers with Written Confirmation (WC) on PharmaCompass.
Zoprace (TN) Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Zoprace (TN) GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Zoprace (TN) GMP manufacturer or Zoprace (TN) GMP API supplier for your needs.
A Zoprace (TN) CoA (Certificate of Analysis) is a formal document that attests to Zoprace (TN)'s compliance with Zoprace (TN) specifications and serves as a tool for batch-level quality control.
Zoprace (TN) CoA mostly includes findings from lab analyses of a specific batch. For each Zoprace (TN) CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Zoprace (TN) may be tested according to a variety of international standards, such as European Pharmacopoeia (Zoprace (TN) EP), Zoprace (TN) JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Zoprace (TN) USP).